Enochian Stock Is Trading Higher On FDA Acceptance of Pre-IND Request For Hepatitis B Program
- Enochian BioSciences Inc (NASDAQ: ENOB) has announced that the FDA has accepted a Pre-IND (Investigational New Drug) request for a potential cure of hepatitis B virus (HBV) infection.
- Written comments are expected this Fall.
- The Pre-IND request was made based on promising data from a proof-of-concept study conducted in chimeric mice, considered by some scientific experts to be the ‘gold standard’ animal model to evaluate HBV cure, the company said in the press release.
- Hepatitis B program is based on a mechanism of action called Hijack RNA that shows promise as a potential platform technology for coronaviruses (including the cause of COVID-19), influenza, and HBV, and are exploring its use against HIV.
- Last month, the company acquired an exclusive license for a technology to potentially treat and prevent all variants of coronavirus, including the cause of COVID-19, as well as influenza.
- Price Action: ENOB shares are up 7.2% at $5.64 during the premarket session on the last check Monday.
- Related content: Benzinga's Full FDA Calendar.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Briefs hepatitis BBiotech News Health Care FDA General
